Sana Biotechnology, Inc. Increase (Decrease) in Accounts Payable
Sana Biotechnology, Inc. (SANA) reported Increase (Decrease) in Accounts Payable of -$397.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$851.00K, a 169.47% decline year-over-year.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $454.00K.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$189.00K, a 108.29% decline year-over-year.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$357.00K.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$3.54M, a 357.44% decline from fiscal 2024.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.38M, a 34.08% increase from fiscal 2023.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.03M, a 2.93% decline from fiscal 2022.
- Sana Biotechnology, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.06M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$851.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$397.00K 10-Q · filed 2026-08-10 | -$586.00K derived: sum of 3 quarters · filed 2026-08-10 | -$943.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $454.00K 10-Q · filed 2026-05-11 | $265.00K derived: sum of 2 quarters · filed 2026-05-11 | -$92.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$546.00K derived: sum of 2 quarters · filed 2026-03-03 | $679.00K derived: sum of 3 quarters · filed 2026-08-10 | -$3.54M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$357.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $868.00K derived: sum of 2 quarters · filed 2026-08-10 | -$3.36M 10-Q · filed 2025-11-06 | -$1.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$3.00M 10-Q · filed 2026-08-10 | -$718.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$4.22M 10-Q · filed 2026-05-11 | -$1.94M derived: sum of 2 quarters · filed 2026-05-11 | -$2.45M derived: sum of 3 quarters · filed 2026-05-11 | -$1.78M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.77M derived: sum of 2 quarters · filed 2026-03-03 | $2.44M derived: sum of 3 quarters · filed 2026-03-03 | $1.38M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $160.00K derived: sum of 2 quarters · filed 2025-11-06 | -$904.00K 10-Q · filed 2025-11-06 | -$2.24M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$397.00K 10-Q · filed 2025-08-11 | -$1.73M derived: sum of 3 quarters · filed 2026-03-03 | $543.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$1.06M 10-Q · filed 2025-05-08 | -$2.40M derived: sum of 2 quarters · filed 2026-03-03 | -$124.00K derived: sum of 3 quarters · filed 2026-03-03 | $317.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $940.00K derived: sum of 2 quarters · filed 2026-03-03 | $1.38M derived: sum of 3 quarters · filed 2026-03-03 | $1.03M 10-K · filed 2026-03-03 |
| 2023-09-30 | $2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.72M derived: sum of 2 quarters · filed 2024-11-08 | $2.36M 10-Q · filed 2024-11-08 | $1.28M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $87.00K 10-Q · filed 2024-08-08 | -$999.00K derived: sum of 3 quarters · filed 2025-03-17 | $482.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$354.00K 10-Q · filed 2024-05-08 | -$1.44M derived: sum of 2 quarters · filed 2025-03-17 | $41.00K derived: sum of 3 quarters · filed 2025-03-17 | -$1.21M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $395.00K derived: sum of 2 quarters · filed 2025-03-17 | -$859.00K derived: sum of 3 quarters · filed 2025-03-17 | $1.06M 10-K · filed 2025-03-17 |
| 2022-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $227.00K derived: sum of 2 quarters · filed 2023-11-08 | $2.14M 10-Q · filed 2023-11-08 | $481.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $663.00K 10-Q · filed 2023-08-03 | -$1.00M derived: sum of 3 quarters · filed 2024-02-29 | $770.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.92M 10-Q · filed 2023-05-08 | $254.00K derived: sum of 2 quarters · filed 2024-02-29 | $2.02M derived: sum of 3 quarters · filed 2024-02-29 | $52.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $107.00K derived: sum of 2 quarters · filed 2024-02-29 | -$1.86M derived: sum of 3 quarters · filed 2024-02-29 | -$266.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$202.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.40M 10-Q · filed 2022-11-02 | $965.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | -$1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$373.00K 10-Q · filed 2022-08-04 | -$805.00K derived: sum of 3 quarters · filed 2023-03-16 | -$255.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $1.60M 10-Q · filed 2022-05-10 | $1.17M derived: sum of 2 quarters · filed 2023-03-16 | $1.72M derived: sum of 3 quarters · filed 2023-03-16 | $1.21M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | -$432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $118.00K derived: sum of 2 quarters · filed 2023-03-16 | -$388.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.98M 10-K · filed 2023-03-16 |
| 2020-09-30 | $550.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $44.00K derived: sum of 2 quarters · filed 2021-11-08 | $2.41M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$506.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.86M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $2.37M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$421.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |